Vaccitech Oncology

Barinthus Biotherapeutics, formerly known as Vaccitech, is a clinical-stage biopharmaceutical company specializing in the development of T cell-inducing immunotherapies. The company utilizes its proprietary ChAdOx and MVA viral vector platforms, originally developed at the University of Oxford, to create a heterologous prime-boost effect that generates high-magnitude T cell responses. Its oncology pipeline focuses on treating solid tumors such as non-small cell lung cancer and prostate cancer by targeting tumor-associated antigens. Beyond oncology, the company is advancing candidates for chronic infectious diseases like Hepatitis B and autoimmune conditions using its SNAP synthetic vaccine platform. Barinthus is headquartered in the UK with significant operations in the United States.